Emily Rooks, MD
Family Medicine · Carrollton, GANPI 1619144722
Payments from drug & device makers
Across 77 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$238
- Amgen$156
- Sanofi-aventis U.S. LLC$134
- Novo Nordisk$90
- Pfizer$88
- Insulet Corporation$61
- plus $579 from 19 others
What the payments were for
- Food & beverage$1,33399%
- Other$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 12 | $238 |
| Amgen | 10 | $156 |
| Sanofi-aventis U.S. LLC | 6 | $134 |
| Novo Nordisk | 5 | $90 |
| Pfizer | 6 | $88 |
| Insulet Corporation | 2 | $61 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Lilly USA, LLC | 4 | $58 |
| AbbVie(2 entities) | 3 | $57 |
| Novartis | 3 | $42 |
| Shire North American Group Inc | 3 | $41 |
| Mallinckrodt Enterprises LLC | 3 | $41 |
| Boehringer Ingelheim | 2 | $41 |
| Merck | 3 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Bayer | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| GSK | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Welch Allyn | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,346 in reported general payments places this provider in the 60th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 206 | $273,228 |
| OzempicSemaglutide | 179 | $262,791 |
| EliquisApixaban | 111 | $126,766 |
| JardianceEmpagliflozin | 66 | $99,760 |
| Repatha SureclickEvolocumab | 96 | $86,306 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $82,426 |
| FarxigaDapagliflozin Propanediol | 51 | $53,996 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $51,273 |
| MyrbetriqMirabegron | 33 | $38,660 |
| JanuviaSitagliptin Phosphate | 36 | $35,112 |
| LinzessLinaclotide | 21 | $28,046 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $24,514 |
| XareltoRivaroxaban | 31 | $23,460 |
| InvokanaCanagliflozin | 13 | $22,215 |
| VascepaIcosapent Ethyl | 23 | $17,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $58 | $273,228206 claims |
| Novo NordiskOzempic | $90 | $262,791179 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $41 | $129,172106 claims |
| PfizerEliquis | $88 | $126,766111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $18 | $99,43199 claims |
| AstraZenecaFarxiga | $15 | $53,99651 claims |
| Johnson & JohnsonXarelto, Invokana | $16 | $45,67444 claims |
| MerckJanuvia, Belsomra | $40 | $42,43853 claims |
| Astellas Pharma US IncMyrbetriq | $238 | $38,66033 claims |
| AbbVieLinzess, Synthroid | $57 | $35,345107 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $134 | $12,14611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Carrollton
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.